Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-072034
Filing Date
2025-05-15
Accepted
2025-05-15 08:34:15
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9045
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 86683
  Complete submission text file 0000950170-25-072034.txt   130731
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Subject) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-58467 | Film No.: 25948937
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014
Business Address 40 10TH AVENUE 7TH FLOOR NEW YORK NY 10014 646-597-6980
RTW INVESTMENTS, LP (Filed by) CIK: 0001493215 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G